問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間:2023-09-19

張立禹
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

8Cases

2025-11-01 - 2030-12-31

Phase II

Active
A phase 2b/3, randomized, double-blind, placebo-controlled, multicenter trial was conducted to investigate the efficacy and safety of lunsekimig in adult subjects with poorly controlled chronic obstructive pulmonary disease (COPD) of the eosinophilic leukocytosis phenotype.
  • Condition/Disease

    The efficacy of lunsekimig was assessed by measuring the annualized incidence of moderate to severe COPD exacerbations.

  • Test Drug

    Lunsekimig/ SAR443765

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2022-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-06-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2014-01-01 - 2018-12-31

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-02-01 - 2025-12-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting6Sites

Terminated6Sites

2026-03-01 - 2031-11-10

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-12-31 - 2029-11-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2024-06-20 - 2027-09-01

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites